Annual Grant Award Dollars
| Investigator | Title | Sponsor | ID | Dates | Amount |
| Raouf Samy Amin, MD | Passive Stretch of the Chest Wall in Patients with Congenital Muscular Dystrophy | Cure CMD | Cure CMD - Amin | 5/3/2013 - 5/2/2016 | $40,000 |
| Raouf Samy Amin, MD | Impact of Treatment of Mild Sleep-Disordered Breathing on Children's Health | National Institutes of Health (Children's Hospital of Philadelphia) | U01 HL125295 | 9/4/2015 - 6/30/2020 | $193,192 |
| Kavisha Arora, PHD | Personalized Medicine-Elucidating Mechanism of a Novel CF Mutation | Cystic Fibrosis Foundation | ARORA16F0 | 3/1/2016 - 2/28/2018 | $46,250 |
| Lisa A Burns, MD | Transforming CF Care Through Shared Decision Making | Cystic Fibrosis Foundation (University of Cincinnati) | JOSEPH15QI0 | 1/1/2015 - 12/31/2017 | $44,107 |
| John Paul Clancy, MD | CFF-TDN site | Cystic Fibrosis Fdn Therapeutics, Inc | AMIN09Y0/CLANCY14Y0 | 1/1/2013 - 12/31/2016 | $96,688 |
| John Paul Clancy, MD | CFFT Biomarkers Consortium | Cystic Fibrosis Fdn Therapeutics, Inc | CLANCY11CS0 | 1/1/2011 - 12/31/2015 | $46,051 |
| John Paul Clancy, MD | PROSPECT | Cystic Fibrosis Fdn Therapeutics, Inc | CLANCY14K1 | 7/1/2014 - 6/30/2019 | $108,731 |
| John Paul Clancy, MD | Pilot Development of Translational Primary Human Airway | Cystic Fibrosis Foundation | CLANCY14XX0 | 7/1/2014 - 6/30/2017 | $95,256 |
| John Paul Clancy, MD | Upper and Lower Airway CF Microbiome: Pediatric Subject Characterization, Sample, Acquisition and Processing | Cystic Fibrosis Fdn Therapeutics, Inc | CLANCY14XX1 | 7/1/2014 - 6/30/2016 | $26,051 |
| John Paul Clancy, MD | TDC ARC Award | Cystic Fibrosis Fdn Therapeutics, Inc | CLANCY14Y4 | 12/1/2014 - 11/30/2016 | $77,153 |
| John Paul Clancy, MD | Personalizing Cystic Fibrosis Research Translation | Cystic Fibrosis Foundation | CLANCY15R0 | 7/1/2015 - 6/30/2019 | $470,000 |
| John Paul Clancy, MD | TDN Steering Committee Chair | Cystic Fibrosis Fdn Therapeutics, Inc | CLANCY16Y3 | 1/1/2016 - 12/31/2018 | $23,138 |
| John Paul Clancy, MD | MR Predictors of Infection, Inflammation, and Structural Lung Damage in CF | National Institutes of Health | R01 HL116226 | 9/26/2012 - 6/30/2017 | $482,554 |
| Zackary Cleveland, PHD | Regional Biomarkers of Peripheral Lung Disease in Cystic Fibrosis | Cystic Fibrosis Fdn Therapeutics, Inc | CLEVEL16A0 | 4/1/2016 - 3/31/2019 | $108,000 |
| Zackary Cleveland, PHD | Time-Resolved 129Xe Ventilation-Perfusion MRI in Models | National Institutes of Health | R00 HL111217 | 8/15/2015 - 7/31/2018 | $248,999 |
| Daniel Grossoehme D.Min. | Training Research-Literate Chaplains as Ambassadors for Spirituality and Health | John Templeton Foundation (Rush Medical University Center) | 51996 | 7/1/2015 - 6/30/2017 | $8,911 |
| William D Hardie, MD John Paul Clancy, MD |
Cincinnati Children's Summer Medical Student Respiratory Research Fellowship | National Institutes of Health | T35 HL113229 | 5/1/2016 - 4/30/2021 | $68,526 |
| James E Heubi, MD | Infant Nutrition Study | Cystic Fibrosis Fdn Therapeutics, Inc (Seattle Children's) | BONUS11K0 | 12/1/2010 - 4/30/2016 | $7,805 |
| Elizabeth Kramer | First and Second Year Clinical Fellowship Grant | Cystic Fibrosis Foundation | KRAMER14B0 | 7/1/2014 - 6/30/2016 | $66,250 |
| Satish K Madala, PHD | Molecular Mechanisms of TGF (alpha)-Driven Pulmonary Fibrosis | Parker B. Francis Fellowship Program | Madala - PBF | 7/1/2013 - 6/30/2016 | $54,000 |
| Gary McPhail, MD | Cystic Fibrosis Center Program Accreditation And Funding | Cystic Fibrosis Foundation | CC160-130 | 7/1/2013 - 6/30/2018 | $144,651 |
| Gary McPhail, MD | Implementation of the Depression & Anxiety Guidelines | Cystic Fibrosis Foundation | CMHC160-15 | 1/1/2016 - 12/31/2018 | $53,246 |
| Gary McPhail, MD | CFF Success with Therapies Research Consortium - Cincinnati Children's | Cystic Fibrosis Fdn Therapeutics, Inc | MCPHAI14PE0 | 8/1/2014 - 7/31/2017 | $27,000 |
| Anjaparavanda Naren, PHD | CF-Patient Specific Enteroids from Small Intestine and Colon | Cystic Fibrosis Fdn Therapeutics, Inc | NAREN14XX0 | 7/1/2014 - 6/30/2017 | $223,357 |
| Anjaparavanda Naren, PHD | Inhibition of an Apical cAMP/cGMP transporter (MRP4) in the Gut induces Diarrhea | National Institutes of Health | R01 DK080834 | 9/18/2013 - 3/31/2018 | $333,536 |
| Anjaparavanda Naren, PHD | LPA2 Receptor-containing Complexes in Regulating Secretory Diarrhea | National Institutes of Health | R01 DK093045 | 7/1/2015 - 6/30/2020 | $351,000 |
| Anjaparavanda Naren, PHD | Characterization of an Inhibitory Protein Complex for Cystic Fibrosis Therapy | National Institutes of Health (Univ of Tennessee Health Science Center) | R01 HL123535 | 8/15/2014 - 6/30/2019 | $17,539 |
| Kai Ruppert, PHD | Simultaneous Xe129 MRI of Regional Lung Ventilation and Gas Uptake in COPD | National Institutes of Health (University of Virginia) | R01 HL109618 | 12/23/2013 - 5/31/2016 | $19,188 |
| Michael Seid, PHD | Enabling Uptake of a Registry-Supported Care and Learning System in the U.S. | Robert Wood Johnson Foundation (Trustees of Dartmouth) | 72313 | 12/15/2014 - 12/14/2017 | $401,775 |
| Michael Seid, PHD | Measures of Hypoglycemia and Glycemic Variability Using Continuous Glucose Monitoring in the FL3X Intervention for Youth with Type 1 Diabetes | The Leona M & Harry B Helmsley Charitable (University of North Carolina) | 2014PG-T1D030 | 1/1/2014 - 12/31/2016 | $10,400 |
| Michael Seid, PHD | A C3N for CF: Design and Development of a Peer-Produced Learning Health System | Cystic Fibrosis Fdn Therapeutics, Inc | SEID14A0 | 7/1/2014 - 12/31/2015 | $277,355 |
| Michael Seid, PHD | A CF C3N Care Model of the Future: Proposal for Piloting a Learning Health System | Cystic Fibrosis Fdn Therapeutics, Inc | SEID15A0 | 1/1/2016 - 12/31/2018 | $800,488 |
| Michael Seid, PHD | FL3X: An Adaptive Intervention to Improve Outcomes for Youth with Type 1 Diabetes | National Institutes of Health (University of North Carolina) | UC4 DK101132 | 9/15/2013 - 6/30/2018 | $629,017 |
| Jason C Woods, PHD | Pathogenesis-Driven Therapeutic Development for Pulmonary Alveolar Microlithiasis | National Institutes of Health (University of Cincinnati) | R01 HL127455 | 4/1/2015 - 3/31/2020 | $70,636 |
| Jason C Woods, PHD John Paul Clancy, MD |
UTE MRI to Monitor CF Lung Disease and Response to CFTR | National Institutes of Health | R01 HL131012 | 5/1/2016 - 3/31/2021 | $760,483 |
| Jason C Woods, PHD | Severe Asthma Research Program | National Institutes of Health (Washington University) | U10 HL109257 | 2/1/2013 - 5/31/2017 | $8,547 |
| Sara M Zak, MD | First & Second Year Clinical Fellowship | Cystic Fibrosis Foundation | ZAK15B0 | 7/1/2015 - 6/30/2017 | $61,250 |
| Assem Ziady, PHD | Dysregulation of Nrf2 in CF Epithelia | National Institutes of Health | R01 HL109362 | 4/22/2015 - 4/30/2016 | $56,933 |
| Total Annual Grant Award Dollars | $6,558,063 | ||||
Annual Industry Award Dollars
| Investigator | Industry Sponsor | Amount |
| John Paul Clancy, MD | Eccrine | $10,000 |
| John Paul Clancy, MD | Nivalis Therapeutics | $209,762 |
| John Paul Clancy, MD | ProQR Therapeutics N.V. | $576,112 |
| Daniel Grossoehme, DMin | Ipsos Insight, LLC | $34,615 |
| Gary McPhail, MD | Parion Services, Inc. | $137,420 |
| Gary McPhail, MD | Vertex Pharmaceutical Incorporated | $82,381 |
| Anjaparavanda Naren, PHD | Ironwood Pharmaceuticals, Inc. | $229,921 |
| Assem Ziady, PHD | Gilead Sciences, Inc. | $66,650 |
| Assem Ziady, PHD | Nivalis Therapeutics | $66,470 |
| Total Annual Industry Award Dollars | $1,413,330 | |
